CTRI/2017/04/008428尚未招募4 期
A Comparative study on evaluation of vilagliptin based regimen vs dapagliflozen based regimen in type 2 diabetic complications
siddhartha medical college0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Males and Females of age between 30-60 years
- •Type â?? 2 diabetics already on treatment but with uncontrolled blood sugars.
- •Type â?? 2 diabetics with hypertension.
- •Type â?? 2 diabetics with obesity
排除标准
- •Males and Females of age above 60 years .
- •Newly diagnosed cases of Type â?? 2. Type â?? 2 diabetics with other endocrinological disorders like hypo or hyperthyroidism, cushingâ??s syndrome and acromegaly, Type â?? 2 diabetics with pancreatic disorders like pancreatitis.
- •, Type â?? 2 Diabetics with acute complications.
- •Type â?? 2 Diabetics on drugs like thiazide diuretics, corticosteroids, oral contraceptive pills, protease inhibitors.
- •Other specific types of diabetes like MODY.
- •Type â?? 2 Diabetics with severe renal failure, heart failure, and hepatic failure.
- •Pregnant & lactating women.
研究者
相似试验
已完成
2 期
Comparison of vildagliptin and alogliptin in patient with type 2 diabetesType 2 diabetes mellitusJPRN-UMIN000005813Yokohama City University Medical Center70
未知
3 期
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220294ovartis Pharma K.K.370
招募中
不适用
Comparison of efficacy and safety of Vildagliptin and Teneligliptin in patients with Type 2 Diabetes MellitusCTRI/2017/02/007766jawaharlal nehru medical college and hospital160
已完成
4 期
Comparison of utility of Viladagliptin 50 mg tablet twice daily and metformin combination therapy with Vildagliptin 100 mg sustained release tablet once daily and metformin combination therapy in Indian patients with type 2 diabetes mellitus: A randomized open label phase IV clinical trialCTRI/2021/10/037574Dr Rudra Paul
未知
3 期
To Compare the Effect with Vildagliptin (50mg qd, 50mg bid or 100mg qd) to Placebo in Patients with Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220283ovartis Pharma K.K.236